Cochlear Ltd is an Australian company that manufactures cochlear implants, which enable hearing in the profoundly deaf. They are listed on the ASX with a market capitalization of over AUD 13 billion and have annual revenues of approximately AUD 1.5 billion, of which emerging markets contribute 20%. They are global leaders in the implantable hearing solution sector, with a market share of over 60%. Cochlear recognizes that future growth is from emerging markets, and Indonesia represents a significant opportunity.

To increase uptake in Indonesia, where implants are not supported by the Government of Indonesia's current national health scheme, Cochlear has partnered with Kasoem Hearing Center and Mitra Keluarga Kelapa Gading Hospital to establish the Jakarta Ear and Hearing Center, a center of excellence for Cochlear implants. All hearing testing, surgery and post-operative support services will be available in one place. Katalis will support the development of a study protocol and potentially secure Ethical Committee approval to conduct a clinical study on implant patients, generating in-country data that Cochlear can utilize to present the benefits of cochlear implants to the Government of Indonesia (GoI).